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not, is still an unresolved issue. There are no clear guidelines.
Elevated TSH at screening, even when of very short dura-
tion, may be a clinically relevant marker of thyroid abnormal-
ities [1]. Data from the Italian National Registry of Infants
with Congenital Hypothyroidism reported an association
between defects of thyroid development and mild increase of
b-TSH at screening. Speciﬁcally, 19.6% of babies with a mild
increase of b-TSH at screening had defects of thyroid develop-
ment (thyroid hypoplasia, hemiagenesis, and ectopy) [2].
However, the European Society for Paediatric Endocrinol-
ogy Consensus Guidelines on Screening, Diagnosis, and Man-
agement of Congenital Hypothyroidism, did not reach a solid
and clear way of management. They stated that ‘‘If venous
TSH concentration isP6 to 20 mU/l beyond 21 days in a well
baby with a FT4 concentration within the limits for age, we
suggest (a) investigation, which should include diagnostic imag-
ing, to try to obtain a deﬁnitive diagnosis; (b) consideration, in
discussion with the family, of either initiating thyroxine
supplementation immediately and retesting, off treatment, at
a later stage; or withholding treatment but retesting two weeks
later’’ [3].
In children with subclinical hypothyroidism, The American
Thyroid Association in 2014 declared that treatment is gener-
ally not recommended when the TSH is 5–10 mIU/L. For
patients with a TSH > 10 mIU/L with signs and symptoms
consistent with primary thyroid disease and/or risk factors
associated with progression, L-T4 replacement may be reason-
able. [Weak recommendation Low quality evidence] [4].
As regards Down syndrome (DS), the therapeutic manage-
ment of subclinical hypothyroidism remains also object of
debate. Very few randomized control trials are presented in
this ﬁeld.
The most important question is whether the TSH elevation
reﬂects mild hypothyroidism that could harm brain growth and
development in the youngest children with DS and contribute
to the ever present mental retardation. An often-used argument
against this hypothesis is the ﬁnding that accompanying plasma
thyroid hormone concentrations generally are within the
age-speciﬁc normal range. In addition, it is unknown whetherthyroid hormone concentrations within the low-normal range
always guarantee optimal thyroid hormone provision of the
developing brain [5].
A wait and see policy with frequent thyroid function screen-
ing could be considered adequate and may be the preferred
strategy, thus avoiding chronic hormonal therapy at least in
Down syndrome patients in whom TSH levels tend to sponta-
neously normalize. A positive anti-TPO antibody test is a key
factor in the follow-up of these patients because of its potential
risk of progression to manifest thyroid disease [6].
Iughetti et al. (2014), suggest that antithyroid antibodies
might represent a marker of deteriorating thyroid function
unlike 1st year TSH levels that do not predict future thyroid
dysfunction requiring therapy, in subjects with DS [7].
Refetoff (2014) would treat hyperthyrotropinemia in DS
only if there is evidence for superimposed autoimmunity [8].
In the last paragraph of the editorial, Elsayed mentioned
that ‘‘L-thyroxine administration will improve growth, hypoto-
nia and psychomotor functions.’’ I would rather use the word
‘‘may’’ instead of ‘‘will’’ improve.
Recently, Bongers-Schokking et al. (2013) reported that
congenital hypothyroidism overtreatment during the ﬁrst
2 years leads to lowered cognitive outcomes at 11 years,
whereas undertreatment, if not complicated by overtreatment,
results in a normal cognitive development [9].
In conclusion, more evidence is required regarding the opti-
mal course of treatment for subclinical hypothyroidism in DS.
Such evidence may be best obtained by conducting a prospec-
tive randomized control trial.References
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